HC Wainwright Rating & Price Target On TherapeuticsMD Under Review On 'Unclear Path'
HC Wainwright Rating & Price Target On TherapeuticsMD Under Review On 'Unclear Path'
HC Wainwright 對 TherapeuticSMD 的評級和目標股價正在審查中，原因是 “路徑不明確”
- The merger agreement between EW Partners and TherapeuticsMD Inc (NASDAQ:TXMD) was terminated, with EW Partners not acquiring the majority of shares to complete the tender offer successfully.
- HC Wainwright said it is unclear what non-tendering shareholders hoped to accomplish.
- The tender offer documents indicated that EW at times considered bids as high as $18/share, so perhaps investors not tendering hoped that EW would increase their bid.
- After the unsuccessful tender and termination of the merger agreement, TherapeuticsMD reached an agreement with its creditors, in which the maturity date of the financing agreement was amended to July 24, 2022.
- TXMD noted that it is considering filing for Chapter 11 bankruptcy or could also try to restart the sale process,
- HC Wainwright's price target and rating are under review as the company seeks to identify a path forward.
- TXMD is not currently generating a profit, and its liquidity could negatively affect the company's ability to sell Annovera, its largest commercial product.
- Price Action: TXMD shares are up 3.13% at $5.45 during the market session on the last check Friday.
- EW Partners和EW Partners之間的合併協議TreateuticsMD公司納斯達克(股票代碼：TXMD)被終止，易居合夥公司未獲得多數股權以成功完成要約收購。
- HC Wainwright表示，目前尚不清楚非競購股東希望實現什麼目標。
- 收購要約文件顯示，EW有時會考慮高達每股18美元的出價，因此，或許沒有投標的投資者希望EW會提高出價。
- 在投標失敗並終止合併協議後，TreeuticsMD與債權人達成協議，將融資協議的到期日修改為2022年7月24日。
- TXMD指出，它正在考慮申請破產保護，或者也可能嘗試重新啟動出售過程。
- HC Wainwright的目標價和評級正在接受審查，該公司正尋求確定一條前進道路。
- TXMD目前沒有盈利，其流動性可能會對該公司銷售其最大商業產品Annovera的能力產生負面影響。
- 價格行動：在週五的最後一次檢查中，TXMD的股價在市場時段上漲了3.13%，達到5.45美元。